70 related articles for article (PubMed ID: 8772232)
21. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
Agren A; Wiman B; Schulman S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
Osmak M; Babić D; Abramić M; Milicić D; Vrhovec I; Skrk J
Neoplasma; 2001; 48(6):462-7. PubMed ID: 11949838
[TBL] [Abstract][Full Text] [Related]
23. Enhanced PAI-1 levels from early second trimester and during labour and plasminogen activators in normal pregnancy.
Koh SC; Anandakumar C; Biswas A; Fong YF
Thromb Haemost; 2002 Jan; 87(1):175-6. PubMed ID: 11858184
[No Abstract] [Full Text] [Related]
24. Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin.
Ritchie H; Robbie LA; Kinghorn S; Exley R; Booth NA
Thromb Haemost; 1999 Jan; 81(1):96-103. PubMed ID: 10348718
[TBL] [Abstract][Full Text] [Related]
25. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Ho CH; Yuan CC; Liu SM
Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
[TBL] [Abstract][Full Text] [Related]
27. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
Robert C; Bolon I; Gazzeri S; Veyrenc S; Brambilla C; Brambilla E
Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092
[TBL] [Abstract][Full Text] [Related]
28. Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients.
Buduneli N; Buduneli E; Ciotanar S; Atilla G; Lappin D; Kinane D
J Clin Periodontol; 2004 Jul; 31(7):556-61. PubMed ID: 15191592
[TBL] [Abstract][Full Text] [Related]
29. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
30. Influence of white blood cells on the fibrinolytic response to sepsis: studies of septic patients with or without severe leucopenia.
Haj MA; Neilly IJ; Robbie LA; Adey GD; Bennett B
Br J Haematol; 1995 Jul; 90(3):541-7. PubMed ID: 7646991
[TBL] [Abstract][Full Text] [Related]
31. Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome.
Wei JL; Cui HM; Ma CY
Eur J Med Res; 2007 May; 12(5):216-21. PubMed ID: 17513194
[TBL] [Abstract][Full Text] [Related]
32. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
[TBL] [Abstract][Full Text] [Related]
33. [The significance of plasminogen activator inhibitor 2 in patients with hematologic malignancies].
Cetkovský P; Koza V; Cepelák V; Vít L
Vnitr Lek; 1993 Sep; 39(9):871-5. PubMed ID: 8212641
[TBL] [Abstract][Full Text] [Related]
34. Plasminogen activator inhibitor type 1 gene polymorphism and sepsis.
Hermans PW; Hazelzet JA
Clin Infect Dis; 2005 Nov; 41 Suppl 7():S453-8. PubMed ID: 16237647
[TBL] [Abstract][Full Text] [Related]
35. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome.
Gando S; Kameue T; Nanzaki S; Nakanishi Y
Thromb Haemost; 1996 Feb; 75(2):224-8. PubMed ID: 8815564
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen Activator Inhibitor 1 for Predicting Sepsis Severity and Mortality Outcomes: A Systematic Review and Meta-Analysis.
Tipoe TL; Wu WKK; Chung L; Gong M; Dong M; Liu T; Roever L; Ho J; Wong MCS; Chan MTV; Tse G; Wu JCY; Wong SH
Front Immunol; 2018; 9():1218. PubMed ID: 29967603
[TBL] [Abstract][Full Text] [Related]
37. [Role of interrelationship of neutrophils, endotheliocytes and mononuclear macrophages in occurrence and course of purulent-septic state. Communication 5. Mechanisms of kinetics of neutrophyl].
Medvats'kyĭ IeB; Zubkov VI; Dubov AM; Vlaĭkov HH; Steblyna VIe; Kryzhevs'kyĭ VV; Lytvynenko OM
Klin Khir; 2004 Jul; (7):51-3. PubMed ID: 15495617
[No Abstract] [Full Text] [Related]
38. [The role of interaction of neutrophil granulocytes, endothelial cells and mononuclear macrophages in pyo-sepsis. Report 3. Structural and functional peculiarities and mechanisms of interaction of "neutrophil granulocyte-endothelial cells"].
Medvets'kyĭ IeB; Zubkov VI; Dubov AM; Vlaĭkov HH; Steblyna VIe; Kryzhevs'kyĭ ; Lytvynenko OM
Klin Khir; 2003 Oct; (10):44-5. PubMed ID: 14730878
[No Abstract] [Full Text] [Related]
39. [The role of interrelationship of neutrophils, endotheliocytes and mononuclear macrophages in occurrence and course of purulent septic states. Report 1. The structural-functional aspects of neutrophil granulocytes].
Medvets'kyĭ IeB; Zubkov VI; Dubov AM; Vlaĭkov HH; Steblyna VIe; Kryzhevs'kyĭ VV; Lytvynenko OM
Klin Khir; 2002 Sep; (8):61-3. PubMed ID: 12378944
[No Abstract] [Full Text] [Related]
40. Ascorbic acid levels in cells may be higher than first believed.
Nutr Rev; 1991 Jan; 49(1):27-8. PubMed ID: 2052169
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
